These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
433 related articles for article (PubMed ID: 16814002)
1. Positron emission tomography/computed tomography in the management of Hodgkin's disease and non-Hodgkin's lymphoma. Rodríguez-Vigil B; Gómez-León N; Pinilla I; Hernández-Maraver D; Coya J; Martín-Curto L Curr Probl Diagn Radiol; 2006; 35(4):151-63. PubMed ID: 16814002 [TBL] [Abstract][Full Text] [Related]
2. Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. la Fougère C; Hundt W; Bröckel N; Pfluger T; Haug A; Scher B; Hacker M; Hahn K; Reiser M; Tiling R Eur J Nucl Med Mol Imaging; 2006 Dec; 33(12):1417-25. PubMed ID: 16858568 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease. Spaepen K; Mortelmans L Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819 [TBL] [Abstract][Full Text] [Related]
4. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420 [TBL] [Abstract][Full Text] [Related]
5. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET? Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979 [TBL] [Abstract][Full Text] [Related]
6. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma. Qiu L; Chen Y; Wu J Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577 [TBL] [Abstract][Full Text] [Related]
7. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Kumar R; Maillard I; Schuster SJ; Alavi A Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559 [TBL] [Abstract][Full Text] [Related]
8. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma. Chiusolo P; Sica S; Leone G Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036 [TBL] [Abstract][Full Text] [Related]
9. The impact of FDG positron emission tomography imaging on the management of lymphomas. Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743 [TBL] [Abstract][Full Text] [Related]
10. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Shen YY; Kao A; Yen RF Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600 [TBL] [Abstract][Full Text] [Related]
11. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging. Lopci E; Burnelli R; Ambrosini V; Nanni C; Castellucci P; Biassoni L; Rubello D; Fanti S Cancer Biother Radiopharm; 2008 Dec; 23(6):681-90. PubMed ID: 19111053 [TBL] [Abstract][Full Text] [Related]
12. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922 [TBL] [Abstract][Full Text] [Related]
14. Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma? Çetin G; Çıkrıkçıoğlu MA; Özkan T; Karatoprak C; Ar MC; Eşkazan AE; Ayer M; Cerit A; Gözübenli K; Uysal BB; Erdem S; Ergül N; Tatar G; Çermik TF Turk J Haematol; 2015 Sep; 32(3):213-9. PubMed ID: 25912844 [TBL] [Abstract][Full Text] [Related]
15. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP; Ryan G; Januszewicz H; Wolf M Am J Med; 2002 Mar; 112(4):262-8. PubMed ID: 11893364 [TBL] [Abstract][Full Text] [Related]
16. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET. Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998 [TBL] [Abstract][Full Text] [Related]
17. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Kasamon YL; Wahl RL Curr Opin Oncol; 2008 Mar; 20(2):206-19. PubMed ID: 18300772 [TBL] [Abstract][Full Text] [Related]
18. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease. Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534 [TBL] [Abstract][Full Text] [Related]